Tong Xin, Song Xiaoxuan, Zhang Yingshi, Zhao Qingchun
Shenyang Pharmaceutical University, Shenyang, China.
Teaching Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command, Shenyang, China.
Arch Physiol Biochem. 2024 Dec;130(6):1005-1011. doi: 10.1080/13813455.2024.2380422. Epub 2024 Jul 31.
Polycystic ovary syndrome (PCOS) is an endocrine gynaecological disorder that affects many women of childbearing age.
To evaluate the efficacy and safety of glucose-like peptide-1 receptor agonists for obese women with PCOS.
We searched the PubMed, Embase, WOS, and Cochrane Libarary databases up to June 2023. Studies were eligible if they were randomised controlled trials (RCTs) comparing GLP-1RAs against any other treatments for patients with PCOS.
Overall, a total of 8 RCTs were included in this review, 7 of the RCTs compared GLP-1RAs with metformin, and 1 RCT compared GLP-1Ras with dapagliflozin. Compared with control group, GLP-1RAs were more effective at improving insulin sensitivity, reducing BMI, and resulting in a smaller waist circumference.
GLP-1RAs may be a good option for obese women with PCOS, especially those with insulin resistance. However, high-quality studies are also needed in the future to assess the efficacy of GLP-1RAs in women with PCOS.
多囊卵巢综合征（PCOS）是一种影响许多育龄女性的内分泌妇科疾病。
评估胰高血糖素样肽-1受体激动剂对肥胖型PCOS女性的疗效和安全性。
我们检索了截至2023年6月的PubMed、Embase、WOS和Cochrane图书馆数据库。纳入的研究需为比较胰高血糖素样肽-1受体激动剂（GLP-1RAs）与其他治疗PCOS患者方法的随机对照试验（RCT）。
总体而言，本综述共纳入8项随机对照试验，其中7项将GLP-1RAs与二甲双胍进行比较，1项将GLP-1RAs与达格列净进行比较。与对照组相比，GLP-1RAs在改善胰岛素敏感性、降低体重指数和减小腰围方面更有效。
GLP-1RAs可能是肥胖型PCOS女性尤其是伴有胰岛素抵抗者的一个良好选择。然而，未来还需要高质量研究来评估GLP-1RAs对PCOS女性的疗效。
